Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 207

Similar articles for PubMed (Select 3055976)

1.

Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients.

Becker DM, Chamberlain B, Swank R, Hegewald MG, Girardet R, Baughman KL, Kwiterovich PO, Pearson TA, Ettinger WH, Renlund D.

Am J Med. 1988 Nov;85(5):632-8.

PMID:
3055976
2.

The determinants of elevated total plasma cholesterol levels in cardiac transplant recipients administered low dose cyclosporine for immunosuppression.

Laufer G, Grablowitz V, Laczkovics A, Miholic J, Heinz G, Wollenek G, Schreiner W, Wolfram J, Wolner E.

J Thorac Cardiovasc Surg. 1992 Aug;104(2):241-7.

PMID:
1495285
3.

Lipoprotein abnormalities in long-term stable liver and renal transplanted patients. A comparative study.

Fernández-Miranda C, de la Calle A, Morales JM, Guijarro C, Aranda JL, Gómez-Sanz R, Gómez-Izquierdo T, Larumbe S, Moreno E, Rodicio JL, del Palacio A.

Clin Transplant. 1998 Apr;12(2):136-41. Erratum in: Clin Transplant 1998 Oct;12(5):487.

PMID:
9575402
4.

Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients.

Penson MG, Fricker FJ, Thompson JR, Harker K, Williams BJ, Kahler DA, Schowengerdt KO.

J Heart Lung Transplant. 2001 Jun;20(6):611-8.

PMID:
11404165
5.

Metabolic risk factors for atherosclerosis in heart transplant recipients.

Kemna MS, Valantine HA, Hunt SA, Schroeder JS, Chen YD, Reaven GM.

Am Heart J. 1994 Jul;128(1):68-72.

PMID:
8017286
6.

A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.

Li JZ, Chen ML, Wang S, Dong J, Zeng P, Hou LW.

Chin Med J (Engl). 2004 Feb;117(2):163-7.

PMID:
14975195
7.

Lipoprotein and hepatic lipase activity and high-density lipoprotein subclasses after cardiac transplantation.

Superko HR, Haskell WL, Di Ricco CD.

Am J Cardiol. 1990 Nov 1;66(15):1131-4.

PMID:
2220641
8.

Hyperlipidemia in long-term survivors of pediatric renal transplantation.

Sharma AK, Myers TA, Hunninghake DB, Matas AJ, Kashtan CE.

Clin Transplant. 1994 Jun;8(3 Pt 1):252-7.

PMID:
8061364
9.

A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease.

Goel PK, Bharti BB, Pandey CM, Singh U, Tewari S, Kapoor A, Garg N, Sinha N.

Indian Heart J. 2003 May-Jun;55(3):234-40.

PMID:
14560932
10.

Effect of immunosuppressive therapy, serum creatinine, and time after transplant on plasma total homocysteine in patients following heart transplantation.

Cook RC, Tupper JK, Parker S, Kingsbury K, Frohlich JJ, Abel JG, Gao M, Ignaszewski AP.

J Heart Lung Transplant. 1999 May;18(5):420-4.

PMID:
10363685
11.

The impact of steroid withdrawal on the development of lipid abnormalities and obesity in heart transplant recipients.

Lake KD, Reutzel TJ, Pritzker MR, Jorgensen CR, Emery RW.

J Heart Lung Transplant. 1993 Jul-Aug;12(4):580-90.

PMID:
8369320
12.

Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients.

Penson MG, Winter WE, Fricker FJ, Harker K, Kahler DA, Kubilis PS, Schowengerdt KO.

J Heart Lung Transplant. 1999 Jul;18(7):707-13.

PMID:
10452348
13.

Risk factors for the development and progression of dyslipidemia after heart transplantation.

Akhlaghi F, Jackson CH, Parameshwar J, Sharples LD, Trull AK.

Transplantation. 2002 Apr 27;73(8):1258-64.

PMID:
11981418
14.

Low levels of high-density lipoprotein cholesterol are associated with vascular remodeling in cardiac transplant recipients.

Ambrose MS, DeNofrio D, Kuvin JT, Pandian NG, Karas RH, Patel AR.

Transplant Proc. 2006 Nov;38(9):3016-20.

PMID:
17112888
15.

Correlates and consequences of diffuse atherosclerosis in men with coronary heart disease. Veterans Affairs High-Density Lipoprotein Intervention Trial Study Group.

Wilt TJ, Rubins HB, Collins D, O'Connor TZ, Rutan GH, Robins SJ.

Arch Intern Med. 1996 Jun 10;156(11):1181-8.

PMID:
8639012
16.

Lipid profiles in pediatric thoracic transplant recipients are determined by their immunosuppressive regimens.

Law YM, Yim R, Agatisa P, Boyle GJ, Miller SA, Lawrence K, Webber SA.

J Heart Lung Transplant. 2006 Mar;25(3):276-82. Epub 2006 Jan 6.

PMID:
16507419
17.

A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus.

Taylor DO, Barr ML, Radovancevic B, Renlund DG, Mentzer RM Jr, Smart FW, Tolman DE, Frazier OH, Young JB, VanVeldhuisen P.

J Heart Lung Transplant. 1999 Apr;18(4):336-45.

PMID:
10226898
18.
19.

Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine.

Vanhaecke J, Van Cleemput J, Van Lierde J, Daenen W, De Geest H.

Transplantation. 1994 Jul 15;58(1):42-5.

PMID:
8036706
20.

Hyperlipidemia in children after heart transplantation.

Singh TP, Naftel DC, Webber S, Dupuis J, Chin C, Spicer R, Schowengerdt KO Jr, Ring WS, Morrow WR; Pediatric Heart Transplant Study Group.

J Heart Lung Transplant. 2006 Oct;25(10):1199-205. Epub 2006 Sep 18.

PMID:
17045932
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk